Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.78 |
| ▸ | AKT1 | P31749 | 1/20 | 0.78 |
| ▸ | ABL1 | P00519 | 6/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.61 |
| ▸ | FYN | P06241 | 3/20 | 0.61 |
| ▸ | CSK | P41240 | 3/20 | 0.61 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.61 |
| ▸ | PRKACA | P17612 | 2/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.61 |
| ▸ | CDK2 | P24941 | 2/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.61 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.61 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.61 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.61 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30175068 | 1.00 | SRC (0.78) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL12436052 | 1.00 | SRC (0.78) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL726813 | 0.90 | SRC (0.64) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL1318810 | 0.89 | SRC (0.79) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL1962110 | 0.88 | SRC (0.66) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL12436150 | 0.87 | AKT1 (1.00) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL13019850 | 0.87 | SRC (1.00) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL409449 | 0.87 | SRC (0.76) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL12436053 | 0.87 | SRC (0.76) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL13019704 | 0.87 | SRC (0.76) | SRCAKT1ABL1RIPK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158034-A1 | CO-TREATMENT WITH CDK4/6 AND CDK2 INHIBITORS TO SUPPRESS TUMOR ADAPTATION TO CDK2 INHIBITORS | PFIZER INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158034-A1 | CO-TREATMENT WITH CDK4/6 AND CDK2 INHIBITORS TO SUPPRESS TUMOR ADAPTATION TO CDK2 INHIBITORS | CDK4, CDK6, CDK2 | SRC 247/4885AKT1 655/4885ABL1 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.